Healthcare company focusing on improving the metabolic and pharmacological profile of drugs through deuterium chemistry Lennham Pharmaceuticals announced having received a patent from United States Patent & Trademark Office (USPTO) covering the administration of a below-normal dose of psilocybin or psilocin to treat neurological or psychiatric disorders in patients suffering from reduced monoamine oxidase A (MAO-A).
The patent was issued under U.S. Patent No. 11,344,564 and it’s accompanied with an expiry date of December 2041. Given the implications to patient safety, the company’s discoveries are presumably expected to cover information in the label of any future psilocybin or psilocin based product related compound.
“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS. Although glucoronidation is psilocin’s primary metabolic route systemically, metabolism by MAO-A plays a much greater role at the site of action. The use of psilocybin or psilocin in patients having an MAO-A deficiency requires a new approach to administration of those products. Our newly issued patent covers methods of using psilocybin and psilocin in these patient populations, which we believe will be incorporated into the eventual labeling for any psilocybin- or psilocin-based product,” said the company’s founder, Bradford C. Sippy.
